Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Sexual Dysfunctions, Psychological 1Salivary Gland Neoplasms 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3trastuzumab deruxtecan 2Cisplatin 2Biopsy 2pembrolizumab 1luprolide acetate gel depot 1entrectinib 1dehydroftorafur 1darolutamide 1ceralasertib 1apalutamide 1amivantamab 1Surveys and Questionnaires 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Platinum 1Pemetrexed 1Leuprolide 1Immunoglobulin G 1Gonadotropin-Releasing Hormone 1Glutamate Carboxypeptidase II 1Fluorouracil 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × Gonadotropin-Releasing Hormone × 30 days × Clear all
NCT04325828 2026-05-08

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting
31 enrolled 15 charts
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡